Caffeine and Sodium Citrate Ingestion - Full Text View

Purpose

A positive ergogenic effect of sodium citrate and caffeine ingestion in a short-term, high-intensity exercise task was shown by several studies. These studies were conducted with healthy, able-bodied subjects.

The aim of the study is to investigate whether caffeine or sodium citrate ingestion could enhance performance in spinal cord injured wheelchair athletes. It is a double blind, placebo controlled and randomized study.

Condition	Intervention
Dietary Supplements Heart Rate/Drug Effects Lactic Acid/Metabolism Physical Education and Training/Methods Wheelchairs	Dietary Supplement: Caffeine Dietary Supplement: Sodium Citrate Dietary Supplement: Mannitol Dietary Supplement: Sodium Chloride


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Factorial Assignment Masking: Double Blind (Participant, Care Provider, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Effects of Caffeine and Sodium Citrate Ingestion in 1500m Wheelchair Racing Athletes

Resource links provided by NLM:

MedlinePlus related topics: Caffeine

Drug Information available for: Sodium citrate

U.S. FDA Resources

Further study details as provided by Swiss Paraplegic Centre Nottwil:

Primary Outcome Measures:

Time [ Time Frame: 3 weeks ]
Time to complete 1500m

Secondary Outcome Measures:

Heart Rate [ Time Frame: during study phase of 3 week (4 tests) ]
Heart Rate measured from 2min before the test until 5min after the 1500m-test.
Lactate Concentration [ Time Frame: during the 3 weeks study phase ]
1min before starting the warm up, 15s after the end of the warm up, 15s after completing the test, 2min/4min/6min/8min/10min after the test
blood pH, sodium concentration and plasma bicarbonate [ Time Frame: during the 3 weeks of study phase ]
1min before starting with the ingestion of the fluid, immediately before starting the warm up, just immediately before starting the 1500m test.
Oxygen Consumption [ Time Frame: during 3 weeks of study phase ]
oxygen consumption (VO2(ml/min/kg), VCO2(ml/min), RER (VCO2/VO2)) starting of the measurement is 2min before the start of the 1500m and ends 2min after having completed the 1500m
rating of gastrointestinal stress [ Time Frame: during the 3 weeks of study phase ]
1min before starting to drink the fluid, 2min before starting with the warm up, 2min before the test and 2min after having completed the 1500m
Rating of Perceived Exertion (RPE) [ Time Frame: during the 3 weeks of study phase ]
15s after the end of the warm up, 15s after having completed the 1500m


Enrollment:	9
Study Start Date:	February 2012
Study Completion Date:	September 2012
Primary Completion Date:	September 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Caffeine 6mg per kg bodyweight ingested 60min before test	Dietary Supplement: Caffeine gelatine capsule 6mg/kg bodyweight 60min prior test Dietary Supplement: Sodium Chloride sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
Placebo Comparator: Placebo Sodium chloride and mannitol as placebo are ingested by the athlete	Dietary Supplement: Mannitol gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test Dietary Supplement: Sodium Chloride sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
Active Comparator: Sodium Citrate sodium citrate diluted in 7dl water, ingestion 120 to 90min prior test	Dietary Supplement: Sodium Citrate 0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test Dietary Supplement: Mannitol gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test
Active Comparator: Caffeine and Sodium Citrate sodium citrate 120-90min prior test capsules:60min prior test	Dietary Supplement: Caffeine gelatine capsule 6mg/kg bodyweight 60min prior test Dietary Supplement: Sodium Citrate 0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test

Detailed Description:

The athletes have to complete four 1500m tests on a training roller. Before each treatment they get different supplementations. Once they get sodium citrate and a placebo, once caffeine and a placebo, once sodium citrate and caffeine and for the fourth treatment they get twice a placebo. Two hours after starting with the supplementation they have to complete the 1500m as fast as possible. Time to complete 1500m, blood pH, plasma bicarbonate, sodium concentration, heart rate, oxygen consumption, blood lactate concentration and rate of perceived exertion (RPE) were measured.

Eligibility


Ages Eligible for Study:	18 Years to 55 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

wheelchair athletes
national team
category T53 and T54

Exclusion Criteria:

medicated
pregnant (for women)
cardiovascular and respiratory diseases

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01591226

Locations


Switzerland
Swiss Paraplegic Centre
Nottwil, Lucerne, Switzerland, 6207

Sponsors and Collaborators

Swiss Paraplegic Centre Nottwil

Investigators


Principal Investigator:	Claudio Perret, Dr. sc. nat.	Swiss Paraplegic Centre Nottwil

More Information


Responsible Party:	Swiss Paraplegic Centre Nottwil
ClinicalTrials.gov Identifier:	NCT01591226 History of Changes
Other Study ID Numbers:	2012-02
Study First Received:	April 3, 2012
Last Updated:	November 21, 2016

Keywords provided by Swiss Paraplegic Centre Nottwil:


caffeine sodium citrate exercise performance wheelchair athletes 1500m

Additional relevant MeSH terms:


Citric Acid Caffeine Mannitol Anticoagulants Calcium Chelating Agents Chelating Agents Sequestering Agents Molecular Mechanisms of Pharmacological Action Central Nervous System Stimulants Physiological Effects of Drugs	Phosphodiesterase Inhibitors Enzyme Inhibitors Purinergic P1 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents Diuretics, Osmotic Diuretics Natriuretic Agents

ClinicalTrials.gov processed this record on July 21, 2017